Wordt geladen...
Managing hyperparathyroidism in hemodialysis: role of etelcalcetide
Secondary hyperparathyroidism (SHPT) is common in patients receiving maintenance hemodialysis and is associated with adverse outcomes. Currently, SHPT is managed by reducing circulating levels of phosphate with oral binders and parathyroid hormone (PTH) with vitamin D analogs and/or the calcimimetic...
Bewaard in:
| Gepubliceerd in: | Int J Nephrol Renovasc Dis |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5804266/ https://ncbi.nlm.nih.gov/pubmed/29440923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJNRD.S128252 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|